Valeant plans to enhance buyout bid for Allergan

05/14/2014 |

Valeant Pharmaceuticals said it planned to improve its nearly $46 billion takeover offer for U.S. firm Allergan to show its commitment to completing the deal, just a day after the latter formally rejected its unsolicited bid. "We are prepared to pay a full and fair price, but consistent with our track record, we will remain financially disciplined," said Valeant Chairman and CEO Michael Pearson in a letter to Allergan shareholders.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC